Spruce Biosciences (SPRB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SPRB Spruce Biosciences

Watchlist

0.442
+0.004+0.82%

Close Sep 27 16:00 ET

0.444
+0.002+0.54%

Post 20:02 ET

18.24MMarket Cap-424P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Yahoo FinanceSep 3 16:01 ET
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
TipRanksAug 20 03:02 ET · Ratings
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
Moomoo NewsAug 19 06:31 ET · Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and ScPharmaceuticals (SCPH)
TipRanksAug 19 06:30 ET · Ratings
Spruce Biosciences Analyst Ratings
BenzingaAug 13 12:27 ET · Ratings
Spruce Biosciences GAAP EPS of -$0.22 Beats by $0.01, Revenue of $1.61M Beats by $0.69M
Seeking AlphaAug 13 10:45 ET

Comments

73372627

Aug 11 02:31

$Zebra Technologies (ZBRA.US)$ and the true of the Spruce analysis

I will never undestend why this company is not investigated for manipulating the market on theirs own interest.
Let's go see why such investigation is neccessary and I hope Zebra will complain.
Spruce it is an Short-selling company which allways made negative reports or analysis in order to influence the market for theyr's own profit. Parallel with Short-selling they are also in real estate managment in New York where they loose b...

Jaguar8

Jun 4 19:13

NEWS

$Spruce Biosciences (SPRB.US)$
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...